Risk factors for cytomegalovirus reactivation after liver transplantation: Can pre-transplant cytomegalovirus antibody titers predict outcome?

Liver Transplantation

Volumn 21, Issue 4, 2015, Pages 539-546

  Bruminhent, Jackrapong ^a,b   Thongprayoon, Charat ^a   Dierkhising, Ross A ^a   Kremers, Walter K ^a   Theel, Elitza S ^a   Razonable, Raymund R ^a  

^a MAYO CLINIC   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; COTRIMOXAZOLE; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN G; INTERLEUKIN 2 RECEPTOR; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY; VALGANCICLOVIR; BIOLOGICAL MARKER; VIRUS ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIBODY TITER; ARTICLE; BODY MASS; BONE MARROW TOXICITY; COLD ISCHEMIA; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; HERPES SIMPLEX; HUMAN; HUMORAL IMMUNITY; INFECTION RISK; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RISK FACTOR; VIRUS REACTIVATION; ADVERSE EFFECTS; BLOOD; CYTOMEGALOVIRUS INFECTIONS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; VIRUS ACTIVATION;

ANTIBODIES, VIRAL; BIOMARKERS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84925866791     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24078     Document Type: Article

References (27)

1. Razonable RR,. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients. Infect Dis Clin North Am 2013; 27: 317-342.
2. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, et al for Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333-360.
3. Bruminhent J, Razonable RR,. Management of cytomegalovirus infection and disease in liver transplant recipients. World J Hepatol 2014; 6: 370-383.
4. Razonable RR, Humar A,; for AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013; 13 (suppl 4): 93-106.
5. Portela D, Patel R, Larson-Keller JJ, Ilstrup DM, Wiesner RH, Steers JL, et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995; 171: 1014-1018.
6. Carbone J, Lanio N, Gallego A, Kern F, Navarro J, Muñoz P, et al. Simultaneous monitoring of cytomegalovirus-specific antibody and T-cell levels in seropositive heart transplant recipients. J Clin Immunol 2012; 32: 809-819.
7. Sarmiento E, Rodriguez-Molina JJ, Fernandez-Yañez J, Palomo J, Urrea R, Muñoz P, et al. IgG monitoring to identify the risk for development of infection in heart transplant recipients. Transpl Infect Dis 2006; 8: 49-53.
8. Sarmiento E, Lanio N, Gallego A, Rodriguez-Molina J, Navarro J, Fernandez-Yañez J, et al. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation. Int Immunopharmacol 2009; 9: 649-652.
9. Cantisán S, Lara R, Montejo M, Redel J, Rodríguez-Benot A, Gutiérrez-Aroca J, et al. Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant 2013; 13: 738-745.
10. Lõpez-Oliva MO, Martinez V, Buitrago A, Jiménez C, Rivas B, Escuin F, et al. Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant. Transplantation 2014; 97: 839-845.
11. Grys TE, Duquette DL, White B, Irish C, Hata DJ, Pritt BS,. Precision across the analytical measuring range of a quantitative real-time PCR assay for cytomegalovirus detection among three clinical laboratories. J Clin Microbiol 2011; 49: 3044-3046.
12. Razonable RR, Brown RA, Espy MJ, Rivero A, Kremers W, Wilson J, et al. Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems. J Clin Microbiol 2001; 39: 4472-4476.
13. Pritt BS, Germer JJ, Gomez-Urena E, Bishop CJ, Mandrekar JN, Irish CL, Yao JD,. Conversion to the COBAS AmpliPrep/COBAS TaqMan CMV test for management of CMV disease in transplant recipients. Diagn Microbiol Infect Dis 2013; 75: 440-442.
14. Shtatland ES, Kleinman K, Cain EM,. Model building in proc phreg with automatic variable selection and information criteria. http://www2.sas.com/proceedings/sugi30/206-30.pdf. Accessed May 14, 2014.
15. Crough T, Khanna R,. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009; 22: 76-98.
16. Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U,. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant 2013; 13: 2601-2610.
17. Preiksaitis JK, Brennan DC, Fishman J, Allen U,. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218-227.
18. Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, Rohrer R,. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 1997; 11: 432-437.
19. Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV,. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection? Liver Transpl 2005; 11: 700-704.
20. Grundy JE, Lui SF, Super M, Berry NJ, Sweny P, Fernando ON, et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988; 2: 132-135.
21. Louie JK, Acosta M, Samuel MC, Schechter R, Vugia DJ, Harriman K, Matyas BT; for California Pandemic (H1N1) Working Group A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis 2011; 52: 301-312.
22. Lo Iacono O, Venezia G, Petta S, Mineo C, De Lisi S, Di Marco V, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 25: 1181-1191.
23. Huttunen R, Syrjänen J,. Obesity and the risk and outcome of infection. Int J Obes (Lond) 2013; 37: 333-340.
24. Foley DP, Fernandez LA, Leverson G, Anderson M, Mezrich J, Sollinger HW, D'Alessandro A,. Biliary complications after liver transplantation from donation after cardiac death donors: an analysis of risk factors and long-term outcomes from a single center. Ann Surg 2011; 253: 817-825.
25. Luan FL, Samaniego M, Kommareddi M, Park JM, Ojo AO,. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients. Transpl Infect Dis 2010; 12: 473-479.
26. Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C,. Antibody induction versus corticosteroid induction for liver transplant recipients. Cochrane Database Syst Rev 2014; 5: CD010252.
27. Lin CC, Chuang FR, Lee CH, Wang CC, Chen YS, Liu YW, et al. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation. Liver Transpl 2005; 11: 1258-1264.